Cargando…

Quality of life in patients with type 2 diabetes after switching to insulin degludec: results from a cross-sectional survey

PURPOSE: Five quality of life (QoL) domains are particularly important to patients with type 2 diabetes (T2D) using basal insulin—sense of physical well-being, sense of safety regarding hypoglycemia, sense of diabetes as burdensome, feelings of freedom and flexibility, and sleep quality. METHODS: An...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uzoigwe, Chioma, Radin, Michael, Hamersky, Carol M., DeKoven, Mitch, Holt, Cassie, Karkare, Swapna, Polonsky, William H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178133/ https://www.ncbi.nlm.nih.gov/pubmed/33550540 http://dx.doi.org/10.1007/s11136-020-02753-6

Ejemplares similares

Impact of a structured patient support program on adherence and persistence in basal insulin therapy for type 2 diabetes
por: Zhou, Fang Liz, et al.
Publicado: (2018)

Assessing Prevalence of Hypoglycemia in a Medical Transcription Database
por: Uzoigwe, Chioma, et al.
Publicado: (2020)

“Real‐World” Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States
por: Larmore, Cynthia, et al.
Publicado: (2015)

When insulin degludec enhances quality of life in patients with type 2 diabetes: a qualitative investigation
por: Weatherall, James, et al.
Publicado: (2018)

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
por: Kalra, Sanjay
Publicado: (2016)

Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial
por: Chaykin, Louis, et al.
Publicado: (2019)

Return-to-Function Following Treatment of Dupuytren Contracture With Collagenase Clostridium Histolyticum Versus Fasciectomy
por: Divino, Victoria M., et al.
Publicado: (2020)

Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2
por: Heller, Simon R., et al.
Publicado: (2019)

Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes
por: Mocarski, Michelle, et al.
Publicado: (2018)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011)

Difficult to swallow: patient preferences for alternative valproate pharmaceutical formulations
por: Bhosle, Monali, et al.
Publicado: (2009)

The economic burden of CIDP in the United States: A case-control study
por: Divino, Victoria, et al.
Publicado: (2018)

In-hospital experience with insulin degludec (IDeg)
por: Bulisani, Maria Gabriela Pedigoni, et al.
Publicado: (2015)

Pediatric diabetes: Potential for insulin degludec
por: Kalra, Sanjay, et al.
Publicado: (2014)

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
por: Liu, Hongzhong, et al.
Publicado: (2021)

Effect of switching basal insulin regimen to degludec on quality of life in Japanese patients with type 1 and type 2 diabetes mellitus
por: Okada, Morihiro, et al.
Publicado: (2015)

Changing direction: a practical approach to directing actors in film and theatre
por: DeKoven, Lenore
Publicado: (2006)

Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study
por: Oe, Yuki, et al.
Publicado: (2022)

Probabilistic data linkage: a case study of comparative effectiveness in COPD
por: Blanchette, Christopher M, et al.
Publicado: (2013)

Clinical and cost outcomes from different hyaluronic acid treatments in patients with knee osteoarthritis: evidence from a US health plan claims database
por: Dasa, Vinod, et al.
Publicado: (2016)

GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data
por: Divino, Victoria, et al.
Publicado: (2019)

A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study)
por: Shimoda, Seiya, et al.
Publicado: (2016)

Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment
por: Kiss, István, et al.
Publicado: (2013)

Degludec: the new ultra-long insulin analogue
por: Tambascia, Marcos Antonio, et al.
Publicado: (2015)

Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

Exploring Why People With Type 2 Diabetes Do or Do Not Persist With Glucagon-Like Peptide-1 Receptor Agonist Therapy: A Qualitative Study
por: Polonsky, William, et al.
Publicado: (2021)

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
por: Kalra, Sanjay
Publicado: (2014)

Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes in Malaysia: Results from a Prospective, Non-interventional Real-World Study
por: Mohamed, Mafauzy, et al.
Publicado: (2023)

Switching Patients with Type 1 Diabetes to Insulin Degludec from Other Basal Insulins: Real-World Data of Effectiveness and Safety
por: Ponzani, Paola, et al.
Publicado: (2019)

Real-World Cost-Effectiveness: Lower Cost of Treating Patients to Glycemic Goal with Liraglutide versus Exenatide
por: DeKoven, Mitch, et al.
Publicado: (2014)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
por: Kalra, Sanjay
Publicado: (2013)

Patient safety and minimizing risk with insulin administration – role of insulin degludec
por: Aye, Myint M, et al.
Publicado: (2014)

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment
por: Kupčová, Viera, et al.
Publicado: (2013)

SUN-179 Prolonged Hypoglycemia from Insulin Degludec
por: Kothari, Vallari, et al.
Publicado: (2019)

Persistent Hypoglycemia Induced by Long-acting Insulin Degludec
por: Katakura, Yukino, et al.
Publicado: (2021)

MON-017 Impact of Hypoglycemia on Behaviors of Patients with Type 2 Diabetes (T2D): A Focus Group Study
por: Wu, Sze-Jung, et al.
Publicado: (2019)

Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007–13) and prospective (2014–18) MIDAS sales data analysis
por: Divino, Victoria, et al.
Publicado: (2016)

GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries
por: Divino, Victoria, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ohm52836ut0941adv4jm9gl2j7